Low-Temperature Photothermal Therapy Platform Based on Pd Nanozyme-Modified Hydrogenated TiO.

In photothermal treatments (PTTs), normal tissues around cancerous tumors get injured by excessive heat, whereas damaged cancer cells are easily restored by stress-induced heat shock proteins (HSPs) at low temperatures. Therefore, to achieve a unique tumor microenvironment (TME), it is imperative to increase PTT efficiency and reduce normal tissue injury by adopting appropriate reactive oxygen species (ROS) and lipid peroxides (LPO) cross-linked with HSPs. In the present research, a potential strategy for mild photothermal treatments (mPTTs) was proposed by initiating localized catalytic chemical reactions in TME based on Pd nanozyme-modified hydrogenated TiO (H-TiO@Pd).

Co-assembled Nanocarriers of Thiol-Activated Hydrogen Sulfide Donors with an RGDFF Pentapeptide for Targeted Therapy of Non-Small-Cell Lung Cancer.

Hydrogen sulfide releasing agents (or HS donors) have been recognized gasotransmitters with potent cytoprotective and anticancer properties. However, the clinical application of HS donors has been hampered by their fast HS-release, instability, and lack of tumor targeting, despite the unclear molecular mechanism of HS action. Here we rationally designed an amphiphilic pentapeptide (RGDFF) to coassemble with the designed thiol-activated HS donors (CL2/3) into nanocarriers for targeted therapy of non-small-cell lung cancer, which has been proved as a one-stone-three-birds strategy.